Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.57 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.57 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.57 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.57 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.57 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25146608 | 0.84 | CHRNB2 (0.52) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL25146761 | 0.84 | CHRNB2 (0.52) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL25146770 | 0.84 | CHRNB2 (0.52) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL23261589 | 0.84 | CHRNB2 (0.43) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL14752168 | 0.84 | CHRNB2 (0.41) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL10119964 | 0.84 | CHRNB2 (0.41) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL19735099 | 0.84 | CHRNB2 (0.41) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL15615861 | 0.83 | CHRNB2 (0.46) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL16999004 | 0.83 | CHRNB2 (0.46) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL18074021 | 0.83 | CHRNB2 (0.46) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240024488-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| WO-2023125708-A1 | P38 MAPK/MK2 PATHWAY MODULATOR, COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海美悦生物科技发展有限公司 | 2023-07-06 | — | — | WO | disclosed |
| US-20230159580-A1 | PYRROLO[2,3-F]INDAZOLE AND 2,4,5,10-TETRAZATRICYCLO[7.3.0.03,7]DODECA-1,3(7),5,8,11-PENTAENE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| US-20220249683-A1 | T-CELL DEPLETING THERAPIES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2022-08-11 | — | — | US | disclosed |
| US-20220177575-A1 | ANTI-CD117 ANTIBODIES AND USES THEREOF | Magenta Therapeutics, Inc. | 2022-06-09 | — | — | US | disclosed |
| US-11059826-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210115018-A1 | PIPERIDINE COMPOUNDS AS COVALENT MENIN INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-04-22 | — | — | US | disclosed |
| US-20170362240-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362240-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20160257686-A1 | Purinone Derivatives as Tyrosine Kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2016-09-08 | — | — | US | disclosed |
| US-9260439-B2 | Dihydropyrrolopyrimidine derivatives | PFIZER INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20150291604-A1 | DIHYDROPYRROLOPYRIMIDINE DERIVATIVES | PFIZER (US) | 2015-10-15 | — | — | US | disclosed |
| US-20140142099-A1 | Purinone Derivatives as Tyrosine Kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-8293736-B2 | Purine compounds selective for PI3K P110 delta, and methods of use | F. HOFFMANN LA ROCHE AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-8119806-B2 | Cicletanine derivatives | MERCK SHARP & DOHME CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20120015931-A1 | PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | US | disclosed |
| US-20100029678-A1 | DIURETICS | MERCK SHARP & DOHME CORP. | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177575-A1 | ANTI-CD117 ANTIBODIES AND USES THEREOF | MYADM, SIGLEC7, ITGB7 | CHRNB2 1101/4885CHRNA3 975/4885CHRNA4 1629/4885 |
| US-20100029678-A1 | DIURETICS | NR3C2, REN, NR3C1 | CHRNB2 331/4885CHRNA3 18/4885CHRNA4 92/4885 |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | NR3C1, NR3C2, MC2R | CHRNB2 504/4885CHRNA3 535/4885CHRNA4 714/4885 |
| US-20140142099-A1 | Purinone Derivatives as Tyrosine Kinase Inhibitors | BMX, BLK, ITK | CHRNB2 4628/4885CHRNA3 4431/4885CHRNA4 3411/4885 |
| US-20210115018-A1 | PIPERIDINE COMPOUNDS AS COVALENT MENIN INHIBITORS | MEN1, BRCA1, PRMT1 | CHRNB2 1758/4885CHRNA3 2043/4885CHRNA4 2835/4885 |
| US-20170362240-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | CHRNB2 4867/4885CHRNA3 4736/4885CHRNA4 4777/4885 |
| US-11059826-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | CHRNB2 4666/4885CHRNA3 4677/4885CHRNA4 4806/4885 |
| US-20240024488-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | CHRNB2 3146/4885CHRNA3 3649/4885CHRNA4 3801/4885 |
| US-20150291604-A1 | DIHYDROPYRROLOPYRIMIDINE DERIVATIVES | DPYD, TPD52L2, DTYMK | CHRNB2 4873/4885CHRNA3 4876/4885CHRNA4 4871/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | CHRNB2 4666/4885CHRNA3 4677/4885CHRNA4 4806/4885 |
| US-20220249683-A1 | T-CELL DEPLETING THERAPIES | CD2, CD4, CD22 | CHRNB2 2438/4885CHRNA3 1701/4885CHRNA4 2093/4885 |
| US-20160257686-A1 | Purinone Derivatives as Tyrosine Kinase Inhibitors | BMX, BLK, ITK | CHRNB2 4628/4885CHRNA3 4431/4885CHRNA4 3411/4885 |
| US-20230159580-A1 | PYRROLO[2,3-F]INDAZOLE AND 2,4,5,10-TETRAZATRICYCLO[7.3.0.03,7]DODECA-1,3(7),5,8,11-PENTAENE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINA3, SERPINC1 | CHRNB2 2952/4885CHRNA3 2222/4885CHRNA4 3643/4885 |
| US-20120015931-A1 | PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CG | CHRNB2 1834/4885CHRNA3 1144/4885CHRNA4 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.